Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. - Wikidata - awgldk - TriplyDB

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

http://www.wikidata.org/entity/Q30423733

about

Advances in structure-based vaccine design Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond Messenger RNA-based vaccines: progress, challenges, applications Animal models for influenza virus pathogenesis, transmission, and immunology Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs mRNA capping: biological functions and applications Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.The notorious R.N.A. in the spotlight - drug or target for the treatment of disease Influence of untranslated regions on retroviral mRNA transfer and expression Full inactivation of human influenza virus by high hydrostatic pressure preserves virus structure and membrane fusion while conferring protection to mice against infection.New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles.Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.Traditional and new influenza vaccines Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.Protein engineering strategies for the development of viral vaccines and immunotherapeutics.Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs Self-replicating alphavirus RNA vaccines.mRNA transcript therapy.Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression.New challenges in therapeutic vaccines against HIV infection.Advances in the delivery of RNA therapeutics: from concept to clinical reality.Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.

P2860

Q26824545-F4059505-6F59-4998-A41E-F5F88C9BAB3F Q26861563-44AA32B1-8310-4C3E-8A82-8509A664EEC9 Q27012738-651C66E7-03C5-4924-B920-F6370845D89B Q27024582-BCB71F59-056B-4DB5-A05F-E7AECB47C602 Q27027078-9633B389-1FDA-4776-ADE6-7E21830FF7C2 Q27303650-A44FF1CE-AA3A-4181-87EC-7B85D1C47B3A Q27469050-CB54260C-FE3F-4BDC-87B7-F02F0292A904 Q30355360-B01B1D7C-630E-4993-B5AB-EA567CEC1306 Q30375250-6CBADDF2-C47A-4C83-A2A8-729FBD666C27 Q30380290-FFD21D8C-0F9D-4831-ADF9-BE3EB5106004 Q30382787-D1C238E1-EB74-4DE1-86D2-6DE4A0480552 Q30397031-283B846C-B5FB-428C-BBC6-46B5223C8CA3 Q30401521-B36C7B95-FEB3-47F3-AF4D-CACCDEE4DFA9 Q33739733-5A6F65A0-F6F4-405F-90A5-3448A8A5CFC2 Q34668961-3E4590D0-4423-4796-88E9-53E7FD2B356C Q35055154-8850DDD9-6BA5-4BEC-9122-CC5399C57577 Q35078213-9E34F51D-A359-4957-9EEF-2DE208BEBFEE Q35600305-5E39D284-97A5-482B-88A5-06307F0980EF Q35746834-7303EEE8-096A-40EE-9735-93366F7EC1E9 Q35826688-319C5774-68A9-4330-8328-3D07EDFD432F Q36104042-A4708AC8-30BD-4FA8-993B-D68CF64751AE Q36185032-D1CDD0D1-2CD4-478D-89A6-798C60FB875F Q36218294-8DC0EBDB-9881-44FD-8D88-4A66B73AD586 Q36757051-69D0B21E-0F11-4F5F-B1ED-07476DFCAD38 Q36977642-BCA72370-6945-4BC0-9488-9D99EF440392 Q37035833-A91852CB-01B5-4648-8E92-E410456DD376 Q37126611-7E2D3EF2-2A66-4AC6-AF6D-D0F1E3E4D5FF Q37263151-DA723CB0-708D-4BCB-B45C-18E7D804C07D Q37530550-268F87A4-1EEB-4280-9731-07DFD356575B Q37625877-58CC6549-D570-4D92-951F-89731A75E0A8 Q37681765-A4B37CCA-8484-4BF3-B239-3BFB87C1B829 Q38157590-7BD0267F-3861-4FF5-83F9-8989375744C9 Q38199151-A848823E-DA44-478A-8F86-10D221E6A02A Q38206520-57569119-9908-4A4E-A03F-0E5D90D670CF Q38255634-FEB7B7E2-008C-4462-A5C7-12FC58A0B49F Q38264088-8E829EE8-E458-468F-ACD9-9645B9F28117 Q38617089-3FA8924E-B059-4D4B-AA99-5311AA8CF4A3 Q38692205-A17330B0-D69E-42CE-89C5-E1BFB63B7265 Q38706445-A5A12D8F-DF39-4B80-9FF5-F51B4F1BE5DD Q38850538-2A4A5133-F8ED-4744-977E-354309E10067

P2860

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

http://www.wikidata.org/entity/Q30423733

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Protective efficacy of in vitr ...... t influenza A virus infection.

@ast

Protective efficacy of in vitr ...... t influenza A virus infection.

@en

type

label

Protective efficacy of in vitr ...... t influenza A virus infection.

@ast

Protective efficacy of in vitr ...... t influenza A virus infection.

@en

prefLabel

Protective efficacy of in vitr ...... t influenza A virus infection.

@ast

Protective efficacy of in vitr ...... t influenza A virus infection.

@en

P1433

Q30423733-F57B705F-4011-4DBA-A39A-290F2D85FEC0

P1476

Q30423733-90F518BC-40DD-48BB-AC75-7CA6CFEE9BB2

P2093

Q30423733-1527B872-747D-4717-BDF2-C04C2B04E217

Q30423733-27811B0E-E04D-4AA5-8A93-340D0DF8965A

Q30423733-400572E2-96DB-4A42-B1C9-23A28F2992CB

Q30423733-62D22F47-20F5-4F63-B34D-91BB80867BA6

Q30423733-6F8D0A41-CCCC-40C6-BE3D-5CE0D3CBA289

Q30423733-7D5DADB1-660A-4245-9A68-A87412E3AF33

Q30423733-96AA9598-B649-439E-BE27-0798C636E8F1

Q30423733-A803D03F-910B-453C-B3B4-F415C05FC12D

Q30423733-C590221F-4802-40F3-91F4-9E04EA52AC10

Q30423733-C5CA0E0F-F3EE-409D-B0B5-441B167D6C48

P2860

Q30423733-00D57F0F-7809-4009-93D3-D8C0072224E1

Q30423733-144BEA2A-2EE2-4AE4-957E-5E2BE72DE512

Q30423733-28B553E9-3F97-4626-8316-82CA17478A37

Q30423733-2DE2F4B5-3BEA-4687-8F88-81BE7D3EF898

Q30423733-2E549A4E-06DB-4177-941A-DE9CE6366954

Q30423733-31BE8331-1533-4AA5-AD23-860700898DEB

Q30423733-4DE624FD-7451-41BD-A5BC-DEB2BF0AADBE

Q30423733-53D7211B-E3C3-4757-8EDE-C108052B3EC5

Q30423733-552A2421-2F91-413C-8DF1-A7DB6D528A9E

Q30423733-595B3F66-1EC4-4278-84C1-2703C4EF99DA

P2888

Q30423733-CDEA9DA6-21C2-438C-B314-0A3CE443E549

P304

Q30423733-7FC0270F-D442-434C-B5EC-3C34E21827FE

P31

Q30423733-0A75F17E-4F6A-4761-8164-B0033F55878C

P356

Q30423733-2D4694BB-C240-4D61-BAFA-06C6788E26CB

P433

Q30423733-253E6403-0981-450D-AD0F-97CBD2E2461E

P478

Q30423733-7DFF1327-E1AA-4F2D-B65B-2A7DD4B3BA32

P577

Q30423733-E729FE09-5DA2-4F4C-BE8D-321C4884AF50

P698

Q30423733-A1C7D02F-26BC-4AFC-AA5F-659D5CCFA770

P356

P1433

Nature Biotechnology

P1476

Protective efficacy of in vitr ...... t influenza A virus infection.

@en

P2093

Andreas Thess

http://www.w3.org/2001/XMLSchema#string

Annette B Vogel

http://www.w3.org/2001/XMLSchema#string

Benjamin Petsch

http://www.w3.org/2001/XMLSchema#string

Bernd Hoffmann

http://www.w3.org/2001/XMLSchema#string

Daniel Voss

http://www.w3.org/2001/XMLSchema#string

Elke Lange

http://www.w3.org/2001/XMLSchema#string

Karl-Josef Kallen

http://www.w3.org/2001/XMLSchema#string

Lothar Stitz

http://www.w3.org/2001/XMLSchema#string

Margit Schnee

http://www.w3.org/2001/XMLSchema#string

Thomas Kramps

http://www.w3.org/2001/XMLSchema#string

P2860

The influenza virus enigma

Intradermal electroporation of naked replicon RNA elicits strong immune responses

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

Animal models in influenza vaccine testing.

Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs.

PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model.

Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs.

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

P2888

P304

1210-1216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.2436

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23159882

http://www.w3.org/2001/XMLSchema#string